ReviewEuropean cardiology2025
New Insights into Uric Acid Metabolism in the Pathophysiology of Ischaemic Heart Disease.
Review in European cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Calcineurin Inhibitors and Uric Acid Control in Solid Organ Transplantation: A Systematic Review.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Drug-induced hyperuricemia: multi-pathway regulation, causative drugs, and individualized management strategies.Frontiers in pharmacology · 2026Review
- Higher serum uric acid levels are associated with an increased risk of carotid atherosclerosis in 67,256 adults.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of hyperuricaemia as an independent cardiovascular risk factor remains controversial and subject to debate. Nonetheless, multiple studies have highlighted the central role of uric acid (UA) in conditions such as hypertension, metabolic syndrome, heart failure and coronary artery disease. Various mechanisms have been proposed to explain UA's involvement in cardiovascular diseases, including through UA-induced oxidative stress, systemic inflammation, endothelial dysfunction and activation of the renin-angiotensin-aldosterone system (RAAS). Asymptomatic hyperuricaemia has been proposed as an independent risk factor for ischaemic heart disease. Nonetheless, the positive impact of urate-lowering therapies on reducing cardiovascular risk still needs to be thoroughly confirmed through large randomised controlled studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.